search button
Open Access

Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4

  • Authors:
    • Xiang-Yuan Song
    • Ya-Ying Chen
    • Wen-Ting Liu
    • Lin Cong
    • Jin-Ling Zhang
    • Yang Zhang
    • Yu-Yan Zhang

  • View Affiliations

  • Published online on: April 13, 2022     https://doi.org/10.3892/ijmm.2022.5132
  • Article Number: 76

  • Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To explore the role of atorvastatin in regulating intraocular pressure (IOP) in glaucoma in vivo, and to investigate its related molecular pathway in vitro, an ocular hypertension model was generated by intravitreal injection of an adenoviral vector encoding transforming growth factor (TGF)‑β2 in the right eye of BALB/cJ mice, while the left was treated with an empty control adenovirus. To determine its anti‑intraocular hypertension role, these induced hyper‑IOP mice were gavaged with atorvastatin (20 mg/kg/day). Furthermore, extracellular matrix (ECM) factors were examined in the primary human trabecular meshwork (HTM) cells followed atorvastatin (0~200 µM) treatment in vitro. Whole genome microarray was employed to identify potential therapeutic target molecules associated with ECM regulation. Unilateral murine ocular hypertension was induced, via intravitreal injection of the adenoviral vector carrying the human TGF‑β2 gene (Ad.hTGF‑β2226/228), raising IOP from 12±1.6 to 32.3±0.7 mmHg (n=6, P<0.05) at day 15, which plateaued from day 15 to 30. Atorvastatin administration from day 15 to 30 decreased IOP from 32.3±0.7 to 15.4±1.1 mmHg (n=6, P<0.05) at day 30. Additionally, atorvastatin administration changed the morphology of cultured HTM cells from an elongated and adherent morphology into rounded, less elongated and less adherent cells, accompanied with suppressed expression of ECM. Gene Ontology and Genome analysis revealed that FGD4 (FYVE, RhoGEF and PH domain containing 4) might be a key factor contributing to these changes. Our data demonstrated that atorvastatin reduced TGF‑β2‑induced ocular hypertension in vivo, perhaps via modifying cellular structure and decreasing ECM, using the FGD4 signaling pathway, as demonstrated in HTM cells. Our findings provide some useful information for the management of glaucoma, with statin therapy revealing a potential novel therapeutic pathway for glaucoma treatment.
View Figures
View References

Related Articles

Journal Cover

June-2022
Volume 49 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 5.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 10.7
  • CiteScore Rank: Q1: #35/328 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.994
  • SCImago Journal Rank (SJR): 0.922
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Song X, Chen Y, Liu W, Cong L, Zhang J, Zhang Y and Zhang Y: Atorvastatin reduces IOP in ocular hypertension <em>in vivo</em> and suppresses ECM in trabecular meshwork perhaps via FGD4. Int J Mol Med 49: 76, 2022
APA
Song, X., Chen, Y., Liu, W., Cong, L., Zhang, J., Zhang, Y., & Zhang, Y. (2022). Atorvastatin reduces IOP in ocular hypertension <em>in vivo</em> and suppresses ECM in trabecular meshwork perhaps via FGD4. International Journal of Molecular Medicine, 49, 76. https://doi.org/10.3892/ijmm.2022.5132
MLA
Song, X., Chen, Y., Liu, W., Cong, L., Zhang, J., Zhang, Y., Zhang, Y."Atorvastatin reduces IOP in ocular hypertension <em>in vivo</em> and suppresses ECM in trabecular meshwork perhaps via FGD4". International Journal of Molecular Medicine 49.6 (2022): 76.
Chicago
Song, X., Chen, Y., Liu, W., Cong, L., Zhang, J., Zhang, Y., Zhang, Y."Atorvastatin reduces IOP in ocular hypertension <em>in vivo</em> and suppresses ECM in trabecular meshwork perhaps via FGD4". International Journal of Molecular Medicine 49, no. 6 (2022): 76. https://doi.org/10.3892/ijmm.2022.5132